WuXi Biologics (Cayman) Inc. (HKG:2269)

WuXi Biologics Revenue

In the year 2025, WuXi Biologics had annual revenue of 21.79B CNY with 16.68% growth. WuXi Biologics had revenue of 11.84B in the half year ending December 31, 2025, with 38.57% growth.

• Revenue: 21.79B CNY
• Revenue Growth: +16.68%
• P/S Ratio: 5.57
• Revenue / Employee: 1.64M CNY
• Employees: 13,252
• Market Cap: 135.14B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	21.79B	3.11B	16.68%
Dec 31, 2024	18.68B	1.64B	9.63%
Dec 31, 2023	17.03B	1.77B	11.56%
Dec 31, 2022	15.27B	4.98B	48.38%
Dec 31, 2021	10.29B	4.68B	83.35%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

May 10, 2026

Data Sources Report a data error